Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FGFR2 | P21802 | 13/20 | 0.44 |
| ▸ | FGFR1 | P11362 | 10/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 7/20 | 0.44 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.42 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.42 |
| ▸ | DAO | P14920 | 1/20 | 0.40 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.37 |
| ▸ | LTA4H | P09960 | 1/20 | 0.37 |
| ▸ | KDR | P35968 | 4/20 | 0.36 |
| ▸ | AURKA | O14965 | 1/20 | 0.36 |
| ▸ | JAK2 | O60674 | 1/20 | 0.36 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.36 |
| ▸ | FLT3 | P36888 | 1/20 | 0.36 |
| ▸ | IGF1R | P08069 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1922681 | 0.90 | CYP19A1 (0.51) | FGFR2FGFR1FGFR3DYRK1ACYP19A1 | |
| SCHEMBL4016450 | 0.80 | DYRK1A (0.58) | FGFR2FGFR1FGFR3DYRK1ACYP19A1 | |
| SCHEMBL3940159 | 0.79 | DYRK1A (0.43) | FGFR2FGFR1FGFR3DYRK1ACYP19A1 | |
| SCHEMBL4012249 | 0.79 | TAAR1 (0.54) | FGFR2FGFR1FGFR3DYRK1ADAO | |
| SCHEMBL4016522 | 0.77 | DYRK1A (0.40) | FGFR2FGFR1FGFR3DYRK1ACYP19A1 | |
| SCHEMBL4012062 | 0.76 | FGFR3 (0.44) | FGFR2FGFR1FGFR3DYRK1ADAO | |
| SCHEMBL17967278 | 0.74 | MKNK1 (0.54) | DAOLTA4H | |
| SCHEMBL23409093 | 0.73 | FGFR2 (0.52) | FGFR2FGFR1FGFR3CYP19A1DAO | |
| SCHEMBL5103566 | 0.72 | FGFR1 (0.59) | FGFR2FGFR1FGFR3KDRIGF1R | |
| SCHEMBL5281973 | 0.72 | TAAR1 (0.55) | CYP19A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2044063-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | Astra Zeneca AB (SE) | 2009-04-08 | — | — | EP | disclosed |
| WO-2008001070-A1 | PYRIMIDINE DERIVATIVES USEFUL IN THE TREATMENT OF CANCER | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | WO | disclosed |
| US-20080004302-A1 | Novel Compounds | ASTRAZENECA AB (SE) | 2008-01-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080004302-A1 | Novel Compounds | CYP11B2, CYP11B1, CYP46A1 | FGFR2 2044/4885FGFR1 1428/4885FGFR3 2897/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.